FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005126818> ?p ?o ?g. }

• W2005126818 endingPage "287" @default.
• W2005126818 startingPage "281" @default.
• W2005126818 abstract "We have shown previously that human apolipoprotein (apo)C1 transgenic mice exhibit hyperlipidaemia, due primarily to an impaired clearance of very-low-density lipoprotein (VLDL) particles from the circulation. In the absence of at least the low-density-lipoprotein receptor (LDLR), it was shown that APOC1 overexpression in transgenic mice inhibited the hepatic uptake of VLDL via the LDLR-related protein. In the present study, we have now examined the effect of apoC1 on the binding of lipoproteins to both the VLDL receptor (VLDLR) and the LDLR. The binding specificity of the VLDLR and LDLR for apoC1-enriched lipoprotein particles was examined in vivo through adenovirus-mediated gene transfer of the VLDLR and the LDLR [giving rise to adenovirus-containing (Ad)-VLDLR and Ad-LDLR respectively] in APOC1 transgenic mice, LDLR-deficient (LDLR-/-) mice and wild-type mice. Remarkably, Ad-VLDLR treatment did not reduce hyperlipidaemia in transgenic mice overexpressing human APOC1, irrespective of both the level of transgenic expression and the presence of the LDLR, whereas Ad-VLDLR treatment did reverse hyperlipidaemia in LDLR-/- and wild-type mice. On the other hand, Ad-LDLR treatment strongly decreased plasma lipid levels in these APOC1 transgenic mice. These results suggest that apoC1 inhibits the clearance of lipoprotein particles via the VLDLR, but not via the LDLR. This hypothesis is corroborated by in vitro binding studies. Chinese hamster ovary (CHO) cells expressing the VLDLR (CHO-VLDLR) or LDLR (CHO-LDLR) bound less APOC1 transgenic VLDL than wild-type VLDL. Intriguingly, however, enrichment with apoE enhanced dose-dependently the binding of wild-type VLDL to CHO-VLDLR cells (up to 5-fold), whereas apoE did not enhance the binding of APOC1 transgenic VLDL to these cells. In contrast, for binding to CHO-LDLR cells, both wild-type and APOC1 transgenic VLDL were stimulated upon enrichment with apoE. From these studies, we conclude that apoC1 specifically inhibits the apoE-mediated binding of triacylglycerol-rich lipoprotein particles to the VLDLR, whereas apoC1-enriched lipoproteins can still bind to the LDLR. The variability in specificity of these lipoprotein receptors for apoC1-containing lipoprotein particles provides further evidence for a regulatory role of apoC1 in the delivery of lipoprotein constituents to different tissues on which these receptors are located." @default.
• W2005126818 created "2016-06-24" @default.
• W2005126818 creator A5024655738 @default.
• W2005126818 creator A5025131217 @default.
• W2005126818 creator A5027663149 @default.
• W2005126818 creator A5033865421 @default.
• W2005126818 creator A5035535699 @default.
• W2005126818 creator A5053350932 @default.
• W2005126818 creator A5062518045 @default.
• W2005126818 creator A5064152035 @default.
• W2005126818 creator A5080530083 @default.
• W2005126818 creator A5080811781 @default.
• W2005126818 date "1999-02-22" @default.
• W2005126818 modified "2023-09-28" @default.
• W2005126818 title "Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor" @default.
• W2005126818 cites W1495673540 @default.
• W2005126818 cites W1502098572 @default.
• W2005126818 cites W1527704744 @default.
• W2005126818 cites W1591191431 @default.
• W2005126818 cites W1600667984 @default.
• W2005126818 cites W1775749144 @default.
• W2005126818 cites W1779355430 @default.
• W2005126818 cites W1787879515 @default.
• W2005126818 cites W1840979539 @default.
• W2005126818 cites W1995618009 @default.
• W2005126818 cites W1997090264 @default.
• W2005126818 cites W2007724393 @default.
• W2005126818 cites W2010715617 @default.
• W2005126818 cites W2019318413 @default.
• W2005126818 cites W2021630929 @default.
• W2005126818 cites W2031053394 @default.
• W2005126818 cites W2032275066 @default.
• W2005126818 cites W2032731208 @default.
• W2005126818 cites W2041197131 @default.
• W2005126818 cites W2050168475 @default.
• W2005126818 cites W2058166721 @default.
• W2005126818 cites W2059120300 @default.
• W2005126818 cites W2059352674 @default.
• W2005126818 cites W2067089828 @default.
• W2005126818 cites W2077568627 @default.
• W2005126818 cites W2082032640 @default.
• W2005126818 cites W2096483531 @default.
• W2005126818 cites W2097151876 @default.
• W2005126818 cites W2102161788 @default.
• W2005126818 cites W2102783561 @default.
• W2005126818 cites W2162330918 @default.
• W2005126818 cites W2346662703 @default.
• W2005126818 cites W2403507619 @default.
• W2005126818 cites W2404445223 @default.
• W2005126818 doi "https://doi.org/10.1042/bj3380281" @default.
• W2005126818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1220053" @default.
• W2005126818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10024503" @default.
• W2005126818 hasPublicationYear "1999" @default.
• W2005126818 type Work @default.
• W2005126818 sameAs 2005126818 @default.
• W2005126818 citedByCount "47" @default.
• W2005126818 countsByYear W20051268182012 @default.
• W2005126818 countsByYear W20051268182014 @default.
• W2005126818 countsByYear W20051268182015 @default.
• W2005126818 countsByYear W20051268182016 @default.
• W2005126818 countsByYear W20051268182017 @default.
• W2005126818 countsByYear W20051268182018 @default.
• W2005126818 countsByYear W20051268182019 @default.
• W2005126818 countsByYear W20051268182022 @default.
• W2005126818 crossrefType "journal-article" @default.
• W2005126818 hasAuthorship W2005126818A5024655738 @default.
• W2005126818 hasAuthorship W2005126818A5025131217 @default.
• W2005126818 hasAuthorship W2005126818A5027663149 @default.
• W2005126818 hasAuthorship W2005126818A5033865421 @default.
• W2005126818 hasAuthorship W2005126818A5035535699 @default.
• W2005126818 hasAuthorship W2005126818A5053350932 @default.
• W2005126818 hasAuthorship W2005126818A5062518045 @default.
• W2005126818 hasAuthorship W2005126818A5064152035 @default.
• W2005126818 hasAuthorship W2005126818A5080530083 @default.
• W2005126818 hasAuthorship W2005126818A5080811781 @default.
• W2005126818 hasBestOaLocation W20051268182 @default.
• W2005126818 hasConcept C102230213 @default.
• W2005126818 hasConcept C104317684 @default.
• W2005126818 hasConcept C126322002 @default.
• W2005126818 hasConcept C134018914 @default.
• W2005126818 hasConcept C141035611 @default.
• W2005126818 hasConcept C170493617 @default.
• W2005126818 hasConcept C185592680 @default.
• W2005126818 hasConcept C2778163477 @default.
• W2005126818 hasConcept C2779134260 @default.
• W2005126818 hasConcept C2780072125 @default.
• W2005126818 hasConcept C43554185 @default.
• W2005126818 hasConcept C55493867 @default.
• W2005126818 hasConcept C57089818 @default.
• W2005126818 hasConcept C62746215 @default.
• W2005126818 hasConcept C71924100 @default.
• W2005126818 hasConcept C8243546 @default.
• W2005126818 hasConcept C86803240 @default.
• W2005126818 hasConceptScore W2005126818C102230213 @default.
• W2005126818 hasConceptScore W2005126818C104317684 @default.
• W2005126818 hasConceptScore W2005126818C126322002 @default.
• W2005126818 hasConceptScore W2005126818C134018914 @default.
• W2005126818 hasConceptScore W2005126818C141035611 @default.

• next